Less potent Pfizer vaccine against Covid-19 variant in lab test


HHello everyone and how are you today? We’re just dandy, despite another blanket of snow coming down on the Pharmalot campus. A picturesque winter scene can be relaxing, right? But there is shoveling in our future. So we’re strengthening ourselves with another cup of stimulation – our pick this morning is mountain blueberries – as we also prepare for a panel that we’ll moderate at 1 p.m. ET today on antibiotic resistance. In the meantime, here are some things of interest that we have put together. Hope your day is going well and you stay safe. …

A lab test suggests that the Covid-19 vaccine made by Pfizer (PFE) and BioNTech (BNTX) is losing some potency against the variant of the coronavirus that first appeared in South Africa, STAT writes. What the results mean for the extent to which the vaccine will protect real people against the variant, called B.1.351, is difficult to say. But clinical data for vaccines made by AstraZeneca (AZN), Novavax (NVAX) and Johnson & Johnson (JNJ) have already shown that they are not as powerful at blocking symptomatic cases of Covid-19 caused by B.1.351 than by other forms of the disease. virus.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!


What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.

What is included?

  • Daily reporting and analysis
  • Industry’s most comprehensive coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to keep you informed of the most important industry news of the day
  • STAT + conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best reporters in the industry
  • The most reliable and most connected newsroom in the healthcare industry
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.

Source link


About Author

Leave A Reply